Quantitative phosphoproteomics analysis reveals broad regulatory role of heparan sulfate on endothelial signaling

Molecular and Cellular Proteomics

Volumn 12, Issue 8, 2013, Pages 2160-2173

  Qiu, Hong ^a,b   Jiang, Jun Lin ^a,b   Liu, Miao ^c   Huang, Xin ^c   Ding, Shi Jian ^c,d   Wang, Lianchun ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b University of Nebraska Medical Center ^*  (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANGIOPOIETIN; CYTOKINE; ERYTHROPOIETIN; GROWTH HORMONE; HEPARAN SULFATE; INTEGRIN; INTEGRIN LINKED KINASE; INTERLEUKIN 17; PHOSPHOPEPTIDE; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SOMATOMEDIN C; THROMBIN; TIE RECEPTOR; VASCULOTROPIN; EXOSTOSIN-1; N ACETYLGLUCOSAMINYLTRANSFERASE; SIGNAL PEPTIDE;

ANIMAL CELL; ARTICLE; BLOOD CLOTTING; CELL ADHESION; CELL COMMUNICATION; CELL CULTURE; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL MOTION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; INFLAMMATION; ISOTOPE LABELING; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ANIMAL; CELL LINE; GENETICS; METABOLISM;

ANIMALS; CELL LINE; ENDOTHELIAL CELLS; HEPARITIN SULFATE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHOSPHOPEPTIDES; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84881103360     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M112.026609     Document Type: Article

References (56)

1. Bishop, J. R., Schuksz, M., and Esko, J. D. (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037
2. Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, M. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777
3. Esko, J. D., and Selleck, S. B. (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471
4. Petitou, M., Casu, B., and Lindahl, U. (2003) 1976-1983, a critical period in the history of heparin: the discoveryof the antithrombin binding site. Biochimie 85, 83-89
5. Kreuger, J., Salmivirta, M., Sturiale, L., Giménez-Gallego, G., and Lindahl, U. (2001) Sequence Analysis of Heparan Sulfate Epitopes with Graded Affinities for Fibroblast Growth Factors 1 and. J. Biol. Chem. 276, 30744-30752
6. Ledin, J., Staatz, W., Li, J. P., Gotte, M., Selleck, S., Kjellén, L., and Spillmann, D. (2004) Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 279, 42732-42741
7. Allen, B. L., Filla, M. S., and Rapraeger, A. C. (2001) Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition. J. Cell Biol. 155, 845-858
8. Franses, J. W., and Edelman, E. R. (2011) The Evolution of Endothelial Regulatory Paradigms in Cancer Biology and Vascular Repair. Cancer Res. 71, 7339-7344
9. Hanahan, D., and Folkman, J. (1996) Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell 86, 353-364
10. Potente, M., Gerhardt, H., and Carmeliet, P. (2011) Basic and Therapeutic Aspects of Angiogenesis. Cell 146, 873-887
11. Fuster, M. M., Wang, L., Castagnola, J., Sikora, L., Reddi, K., Lee, P. H., Radek, K. A., Schuksz, M., Bishop, J. R., Gallo, R. L., Sriramarao, P., and Esko, J. D. (2007) Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J. Cell Biol. 177, 539-549
12. Wang, L., Fuster, M., Sriramarao, P., and Esko, J. D. (2005) Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 6, 902-910
13. Dai, E., Liu, L. Y., Wang, H., McIvor, D., Sun, Y. M., Macaulay, C., King, E., Munuswamy-Ramanujam, G., Bartee, M. Y., Williams, J., Davids, J., Charo, I., McFadden, G., Esko, J. D., and Lucas, A. R. (2010) Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection. PLoS One. 5, e10510
14. Zuberi, R. I., Ge, X. N., Jiang, S., Bahaie, N. S., Kang, B. N., Hosseinkhani, R. M., Frenzel, E. M., Fuster, M. M., Esko, J. D., Rao, S. P., and Sriramarao, P. (2009) Deficiency of endothelial heparan sulfates attenuates allergic airway inflammation. J. Immunol. 183, 3971-3979
15. Bao, X., Moseman, E. A., Saito, H., Petryniak, B., Petryniak, B., Thiriot, A., Hatakeyama, S., Ito, Y., Kawashima, H., Yamaguchi, Y., Lowe, J. B., von Andrian, U. H., and Fukuda, M. (2010) Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. Immunity. 33, 817-829
16. Axelsson, J., Xu, D., Kang, B. N., Nussbacher, J. K., Handel, T. M., Ley, K., Sriramarao, P., and Esko, J. D. (2012) Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood. 120, 1742-1751
17. Xu, D., Fuster, M. M., Lawrence, R., and Esko, J. D. (2011) Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability. J. Biol. Chem. 286, 737-745
18. Yin, X., Truty, J., Lawrence, R., Johns, S. C., Srinivasan, R. S., Handel, T. M., and Fuster, M. M. (2010) A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis. Mol. Cancer. 9, 316
19. Fuster, M. M., and Wang, L. (2010) Endothelial heparan sulfate in angiogenesis. Prog Mol. Biol. Transl. Sci. 93, 179-212
20. Lim, W. A., and Pawson, T. (2010) Phosphotyrosine Signaling: Evolving a New Cellular Communication System. Cell 142, 661-667
21. Ding, S. J., Wang, Y., Jacobs, J. M., Qian, W. J., Yang, F., Tolmachev, A. V., Du, X., Wang, W., Moore, R. J., Monroe, M. E., Purvine, S. O., Waters, K., Heibeck, T. H., Adkins, J. N., Camp, D. G., 2nd, Klemke, R. L., and Smith, R. D. (2008) Quantitative phosphoproteome analysis of lysophosphatidic acid induced chemotaxis applying dual-step (18)O labeling coupled with immobilized metal-ion affinity chromatography. J Proteome Res. 7, 4215-4224
22. Wang, Y., Ding, S. J., Wang, W., Jacobs, J. M., Qian, W. J., Moore, R. J., Yang, F., Camp, D. G., 2nd, Smith, R. D., and Klemke, R. L. (2007) Profiling signaling polarity in chemotactic cells. Proc. Natl. Acad. Sci. U.S.A. 104, 8328-8333
23. Kraushaar, D. C., Yamaguchi, Y., and Wang, L. (2010) Heparan sulfate is required for embryonic stem cells to exit from self-renewal. J. Biol. Chem. 285, 5907-5916
24. Kraushaar, D. C., Rai, S., Condac, E., Nairn, A., Zhang, S., Yamaguchi, Y., Moremen, K., Dalton, S., and Wang, L. (2012) Heparan Sulfate Facilitates FGF and BMP Signaling to Drive Mesoderm Differentiation of Mouse Embryonic Stem Cells. J. Biol. Chem. 287, 22691-22700
25. Wijelath, E., Namekata, M., Murray, J., Furuyashiki, M., Zhang, S., Coan, D., Wakao, M., Harris, R. B., Suda, Y., Wang, L., and Sobel, M. (2010) Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J. Cell. Biochem. 111, 461-468
26. Muller, W. J., Naujokas, M. A., and Hassell, J. A. (1984) Isolation of large T antigen-producing mouse cell lines capable of supporting replication of polyomavirus-plasmid recombinants. Mol. Cell. Biol. 4, 2406-2412
27. Inatani, M., Irie, F., Plump, A. S., Tessier-Lavigne, M., and Yamaguchi, Y. (2003) Mammalian Brain Morphogenesis and Midline Axon Guidance Require Heparan Sulfate. Science 302, 1044-1046
28. Zhang, B., Dietrich, U. M., Geng, J. G., Bicknell, R., Esko, J. D., and Wang, L. (2009) Repulsive axon guidance molecule Slit3 is a novel angiogenic factor. Blood 114, 4300-4309
29. Qiu, H., Yang, B., Pei, Z. C., Zhang, Z., and Ding, K. (2010) WSS25 Inhibits Growth of Xenografted Hepatocellular Cancer Cells in Nude Mice by Disrupting Angiogenesis via Blocking Bone Morphogenetic Protein (BMP)/Smad/Id1 Signaling. J. Biol. Chem. 285, 32638-32646
30. Zhang, S., Condac, E., Qiu, H., Jiang, J., Gutierrez-Sanchez, G., Bergmann, C., Handel, T., and Wang, L. (2012) Heparin-induced leukocytosis requires 6-O-sulfation and is caused by blockade of selectin- and CXCL12 protein-mediated leukocyte trafficking in mice. J. Biol. Chem. 287, 5542-5553
31. Hou, J., Dong, J., Sun, L., Geng, L., Wang, J., Zheng, J., Li, Y., Bridge, J., Hinrichs, S. H., and Ding, S. J. (2011) Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU112. J. Transl. Med. 9, 64
32. Harsha, H. C., Molina, H., and Pandey, A. (2008) Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat. Protoc. 3, 505-516
33. Villén, J., and Gygi, S. P. (2008) The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nat. Protoc. 3, 1630-1638
34. Sugiyama, N., Masuda, T., Shinoda, K., Nakamura, A., Tomita, M., and Ishihama, Y. (2007) Phosphopeptide Enrichment by Aliphatic Hydroxy Acid-modified Metal Oxide Chromatography for Nano-LC-MS/MS in Proteomics Applications. Mol. Cell. Proteomics. 6, 1103-1109
35. Shilov, I. V., Seymour, S. L., Patel, A. A., Loboda, A., Tang, W. H., Keating, S. P., Hunter, C. L., Nuwaysir, L. M., and Schaeffer, D. A. (2007) The Paragon Algorithm, a Next Generation Search Engine That Uses Sequence Temperature Values and Feature Probabilities to Identify Peptides from Tandem Mass Spectra. Mol. Cell. Proteomics. 6, 1638-1655
36. Liu, M., Hou, J., Huang, L., Huang, X., Heibeck, T. H., Zhao, R., Pasa-Tolic, L., Smith, R. D., Li, Y., Fu, K., Zhang, Z., Hinrichs, S. H., and Ding, S. J. (2010) Site-specific proteomics approach for study protein S-nitrosylation. Anal. Chem. 82, 7160-7168
37. Chalkley, R. J., and Clauser, K. R. (2012) Modification Site Localization Scoring: Strategies and Performance. Mol. Cell. Proteomics. 11, 3-14
38. Huang, da, W., Sherman, B. T., and Lempicki, R. A. (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57
39. Johnson, C. E., Crawford, B. E., Stavridis, M., Ten Dam, G., Wat, A. L., Rushton, G., Ward, C. M., Wilson, V., van Kuppevelt, T. H., Esko, J. D., Smith, A., Gallagher, J. T., and Merry, C. L. (2007) Essential alterations of heparan sulfate during the differentiation of embryonic stem cells to Sox1-enhanced green fluorescent protein-expressing neural progenitor cells. Stem Cells 25, 1913-1923
40. Wu, X., Tian, L., Li, J., Zhang, Y., Han, V., Li, Y., Xu, X., Li, H., Chen, X., Chen, J., Jin, W., Xie, Y., Han, J., and Zhong, C. Q. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol. Cell. Proteomics. 11, 1640-1651
41. Mann, M., Ong, S. E., Gronborg, M., Steen, H., Jensen, O. N., and Pandey, A. (2002) Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol. 20, 261-268
42. Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T., and Gallagher, J. T. (1994) Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269, 11216-11223
43. Beattie, J., Phillips, K., Shand, J. H., Szymanowska, M., Flint, D. J., and Allan, G. J. (2005) Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein -3/5 (IGFBP-3/5) heparin axis. J. Mol. Endocrinol. 34, 163-175
44. Yu, H., and Rohan, T. (2000) Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression. J. Natl. Cancer Inst. 92, 1472-1489
45. Booth, B. A., Boes, M., Andress, D. L., Dake, B. L., Kiefer, M. C., Maack, C., Linhardt, R. J., Bar, K., Caldwell, E. E., and Weiler, J. (1995) IGFBP-3 and IGFBP-5 association with endothelial cells: roles of C-terminal heparin binding domain. Growth Regulation. 5, 1-17
46. Sarrazin, S., Lamanna, W. C., and Esko, J. D. (2011) Heparan Sulfate Proteoglycans. Cold Spring Harb Perspect Biol. 3
47. Ori, A., Wilkinson, M. C., and Fernig, D. G. (2011) A Systems Biology Approach for the Investigation of the Heparin/Heparan Sulfate Interactome. J. Biol. Chem. 286, 19892-19904
48. Petrillo, M., Scambia, G., and Ferrandina, G. (2012) Novel targets for VEGF-independent anti-Angiogenic drugs. Expert Opin. Investig. Drugs 21, 451-472
49. Crawford, Y., and Ferrara, N. (2009) Tumor and stromal pathways mediating refractoriness/resistance to anti-Angiogenic therapies. Trends Pharmacol. Sci. 30, 624-630
50. Bergers, G., and Hanahan, D. (2008) Modes of resistance to anti-Angiogenic therapy. Nat. Rev. Cancer 8, 592-603
51. Anower-E-Khuda, M. F., Matsumoto, K., Habuchi, H., Morita, H., Yokochi, T., Shimizu, K., and Kimata, K. (2013) Glycosaminoglycans in blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application. Glycobiology (in press)
52. Kuo, W. J., Digman, M. A., and Lander, A. D. (2010) Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization. Mol. Biol. Cell. 21, 4028-4041
53. Grant, M. B., Mames, R. N., Fitzgerald, C., Ellis, E. A., Aboufriekha, M., and Guy, J. (1993) Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 36, 282-291
54. Grant, M. B., Mames, R. N., Fitzgerald, C., Ellis, E. A., Caballero, S., Chegini, N., and Guy, J. (1993) Insulin-like growth factor I as an angiogenic agent in vivo and in vitro studies. Ann. N.Y. Acad. Sci. 692, 230-242
55. Aghdam, S. Y., Eming, S. A., Willenborg, S., Neuhaus, B., Niessen, C. M., Partridge, L., Krieg, T., and Bruning, J. C. (2012) Vascular endothelial insulin/IGF-1 signaling controls skin wound vascularization. Biochem. Biophys. Res. Commun. 421, 197-202
56. Richardson, M. R., Lai, X., Witzmann, F. A., and Yoder, M. C. (2010) Venous and arterial endothelial proteomics: mining for markers and mechanisms of endothelial diversity. Expert Rev Proteomics. 7, 823-831